Industry news that matters to you.  Learn more

Archives for March 2016

Craft Technologies, Inc. to Improve Identification of Nutrition Deficiencies

Craft Technologies, Inc. (CTI) received funding for the next two years from the Bill & Melinda Gates Foundation to determine appropriate methods to collect and measure Nutritional Biomarkers (NBs) in Dried Matrix Spots (DMS). Dried Blood Spots (DBS) have been used for nearly 50 years to screen neonates for phenylketonuria. During the past 10 years, DBS have become widely accepted in the biomedical and pharmaceutical communities. DBS suffer from inherent problems related to accuracy and stability. Now, more sophisticated devices of sample collection have been developed which separate red blood cells from serum. CTI will evaluate available sample collection devices by measuring the accuracy and stability of 11 nutritional biomarkers in blood samples and establish optimal procedures to achieve economical and robust methods for collection and analysis.

New Study Shows that Genetic Information from Prostate Needle Biopsy May Be Used to Predict Tumor Aggressiveness

GenomeDx Biosciences recently announced results from a new study which demonstrates the ability to measure and evaluate biomarkers from RNA expression data obtained from prostate needle biopsies. The data demonstrate a high concordance in the genomic signatures between needle biopsy samples and post-prostatectomy tissue samples, providing preliminary evidence that the Decipher score may be predictive of disease progression following biopsy as well as following prostate surgery.

Critical Diagnostics Inks Exclusive Worldwide License Agreement for New Heart Failure Biomarker sNEP

Critical Diagnostics recently announced that it has entered into a license agreement for the exclusive worldwide rights to the use of the biomarker soluble neprilysin (sNEP) in the diagnosis and monitoring of heart failure patients. Health Sciences Research Institute Germans Trias i Pujol Foundation (IGTP) of Barcelona Spain is the licensor.

A Handful of Biologists Went Rogue and Published Directly to the Internet

On Feb. 29, Carol Greider of Johns Hopkins University became the third Nobel Prize laureate biologist in a month to do something long considered taboo among biomedical researchers: She posted a report of her recent discoveries to a publicly accessible website, bioRxiv, before submitting it to a scholarly journal to review for “official’’ publication.

It was a small act of information age defiance, and perhaps also a bit of a throwback, somewhat analogous to Stephen King’s 2000 self-publishing an e-book or Radiohead’s 2007 release of a download-only record without a label. To commemorate it, she tweeted the website’s confirmation under the hashtag #ASAPbio, a newly coined rallying cry of a cadre of biologists who say they want to speed science by making a key change in the way it is published.

Smithers Avanza Expands Bioanalytical Laboratory

Smithers Avanza, a contract research organization supporting the pharmaceutical industry, announced that its Bioanalytical Services Division has completed an expansion of its bioanalytical laboratory. This expansion will accommodate a 33 percent increase in staff in support of client needs during the development of large molecule biologic therapies.